In the Claims

Please make the following amendments in the claims:

Please cancel Claims 20-21 and 24-35 without prejudice to filing future continuing applications.

1-19. (canceled)

20. (canceled) ~~A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

21. (canceled) ~~A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50~~,

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~

~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~

~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~

~~or a salt thereof to said mammal.~~

22. (amended) A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence ~~selected from the group consisting~~ of

~~(i) the amino acid sequence represented by~~ SEQ ID NO: 5,

~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 47, and~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 61~~,

or a salt thereof to said mammal.

23. (amended) A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering **a pharmaceutical composition comprising** a ligand polypeptide having an amino acid sequence ~~represented by~~ **of** SEQ ID NO: ~~61~~ **5**, or a salt thereof**, and a pharmaceutically acceptable carrier, excipient or diluent,** to said mammal.

24. (canceled) ~~A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~25.~~ (canceled) ~~A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~

~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~

~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~

~~or a salt thereof to said mammal.~~

~~26.~~ (canceled) ~~A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 47, and~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 61,~~

~~or a salt thereof to said mammal.~~

~~27.~~ (canceled) ~~A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~

~~28~~(canceled) ~~A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~29.~~ (canceled) ~~A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the~~

~~group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~

~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~

~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~

~~or a salt thereof to said mammal.~~

~~30.~~ (canceled) ~~A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 61, and~~

~~or a salt thereof to said mammal.~~

~~31.~~ (canceled) ~~A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~

~~32.~~ (canceled) ~~A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~33.~~ (canceled) ~~A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~

~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~

~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~

~~or a salt thereof to said mammal.~~

~~34.~~ (canceled) ~~A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 61, and~~

~~or a salt thereof to said mammal.~~

~~35.~~ (canceled) ~~A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~